BR112012013952A2 - pharmaceutical formulation of nanoparticles and their preparation methods and uses - Google Patents

pharmaceutical formulation of nanoparticles and their preparation methods and uses

Info

Publication number
BR112012013952A2
BR112012013952A2 BR112012013952-5A BR112012013952A BR112012013952A2 BR 112012013952 A2 BR112012013952 A2 BR 112012013952A2 BR 112012013952 A BR112012013952 A BR 112012013952A BR 112012013952 A2 BR112012013952 A2 BR 112012013952A2
Authority
BR
Brazil
Prior art keywords
nanoparticles
hsa
photosensitizer
nanoparticle
pharmaceutical formulation
Prior art date
Application number
BR112012013952-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Langer Klaus
Wacker Matthias
Röder Beate
Pruess Annegret
Albrecht Volker
Gräfe Susanna
Wiehe Arno
Von Briesen Hangen
Wagner Sylvia
Original Assignee
Biolitec Pharma Marketing Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolitec Pharma Marketing Ltd. filed Critical Biolitec Pharma Marketing Ltd.
Publication of BR112012013952A2 publication Critical patent/BR112012013952A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112012013952-5A 2009-12-11 2010-12-08 pharmaceutical formulation of nanoparticles and their preparation methods and uses BR112012013952A2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28590209P 2009-12-11 2009-12-11
US61/285,902 2009-12-11
US12/941,350 US9211283B2 (en) 2009-12-11 2010-11-08 Nanoparticle carrier systems based on human serum albumin for photodynamic therapy
US12/941,350 2010-11-08
PCT/US2010/059364 WO2011071968A2 (en) 2009-12-11 2010-12-08 Nanoparticle carrier systems based on human serum albumin for photodynamic therapy

Publications (1)

Publication Number Publication Date
BR112012013952A2 true BR112012013952A2 (en) 2018-06-05

Family

ID=44143223

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012013952-5A BR112012013952A2 (en) 2009-12-11 2010-12-08 pharmaceutical formulation of nanoparticles and their preparation methods and uses

Country Status (7)

Country Link
US (1) US9211283B2 (https=)
EP (1) EP2509620A4 (https=)
JP (1) JP5972171B2 (https=)
CN (1) CN102740875A (https=)
BR (1) BR112012013952A2 (https=)
CA (1) CA2784001C (https=)
WO (1) WO2011071968A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2591803A1 (de) * 2011-11-09 2013-05-15 APOCARE Pharma GmbH Zusammensetzung für die photodynamische Diagnostik und Therapie von Tumoren
CN103169968B (zh) * 2013-03-12 2014-11-26 中国科学院理化技术研究所 一种基于白蛋白的疏水二氢卟吩光敏剂纳米药物制剂、制备方法及其应用
KR101329646B1 (ko) * 2013-05-02 2013-11-14 주식회사 지니스 표적지향증폭형 항암나노입자 및 이의 제조방법
EP3201201B1 (en) 2014-09-30 2022-01-26 biolitec unternehmensbeteiligungs II AG Specifically meso-substituted porphyrins and chlorins for photodynamic therapy
CN104587466B (zh) * 2014-12-15 2017-11-21 苏州大学 蛋白‑聚吡咯复合物及蛋白‑聚吡咯复合物衍生物的制备方法与应用
ES3011714T3 (en) 2016-02-26 2025-04-08 Biolitec Holding Gmbh & Co Kg Conjugates of porphyrinoid photosensitizers and glycerol-based polymers for photodynamic therapy
DE102016125666A1 (de) * 2016-12-23 2018-06-28 Michael Denck HSA-Galenik
JP7110360B2 (ja) 2017-10-09 2022-08-01 テルモ ビーシーティー バイオテクノロジーズ，エルエルシー 凍結乾燥方法
WO2020120474A1 (en) 2018-12-10 2020-06-18 Universität Hamburg Specifically glyco-substituted porphyrins and chlorins for photodynamic therapy
CN113614477B (zh) 2019-03-14 2023-04-28 泰尔茂比司特生物技术有限公司 冷冻干燥装载托盘组件及系统
CN110251672B (zh) * 2019-06-18 2022-04-01 深圳大学 一种纳米诊疗剂及其制备方法与应用
CN111110861B (zh) * 2020-02-23 2023-08-25 上海交通大学医学院附属瑞金医院 一种基于人血清白蛋白的载药颗粒及其制备方法
CN112972676B (zh) * 2020-08-17 2024-09-24 滨州医学院 HSA-Biotin-DDA-TCPP分子的合成及其作为光动力治疗剂及纳米药的应用
WO2022074014A1 (en) * 2020-10-05 2022-04-14 Biolitec Unternehmensbeteiligungs Ii Ag Tetrapyrrole-based compounds and their formulations for anti-microbial therapy
CN113855645B (zh) * 2021-09-13 2024-02-02 苏州大学 一种基于功能化蛋白质纳米粒的核壳型组装体及其制备方法与应用
WO2023039691A1 (zh) * 2021-09-17 2023-03-23 苏州大学 一种基于功能化蛋白质纳米粒的核壳型组装体及其制备方法与应用
CA3231406A1 (en) * 2021-09-17 2023-03-23 Huang-chiao HUANG Amorphous photosensitizing particles, methods for the preparation thereof, and methods for the use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8805849D0 (en) 1988-03-11 1988-04-13 Efamol Holdings Porphyrins & cancer treatment
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
GB9420355D0 (en) * 1994-10-10 1994-11-23 Univ Nottingham Preparation of protein microspheres, films and coatings
US5648485A (en) 1994-10-26 1997-07-15 University Of British Columbia β, β-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins
US6649192B2 (en) * 1996-07-29 2003-11-18 Universidade De Santiago De Compostela Application of nanoparticles based on hydrophilic polymers as pharmaceutical forms
WO2000061584A1 (en) 1999-04-14 2000-10-19 The University Of British Columbia IMPROVED β,β,-DIHYDROXY MESO-SUBSTITUTED CHLORINS, ISOBACTERIOCHLORINS, AND BACTERIOCHLORINS
DE60032372T2 (de) 1999-09-23 2007-10-11 Dabur Pharma Ltd., New Delhi Arzneizubereitungen enthaltend paclitaxel eingeschlossen in nanopartikeln von polymerischen mizellen
US20030103995A1 (en) * 2001-06-04 2003-06-05 Hamblin Michael R. Detection and therapy of vulnerable plaque with photodynamic compounds
US7455858B2 (en) 2002-05-16 2008-11-25 Qlt Inc. Compositions and methods for delivery of photosensitive drugs
US8709449B2 (en) * 2004-02-12 2014-04-29 Biolitec Pharma Marketing Ltd Methods and compositions for improving photodynamic therapy through administration of lipids
DE102004011776A1 (de) * 2004-03-09 2005-11-03 Lts Lohmann Therapie-Systeme Ag Trägersystem in Form von Nanopartikeln auf Proteinbasis zur zellspezifischen Anreicherung von pharmazeutisch aktiven Wirkstoffen
JP2006056807A (ja) * 2004-08-18 2006-03-02 Konica Minolta Medical & Graphic Inc 光線力学療法製剤
US20070218049A1 (en) * 2006-02-02 2007-09-20 Wei Chen Nanoparticle based photodynamic therapy and methods of making and using same
WO2006133271A2 (en) * 2005-06-06 2006-12-14 The General Hospital Corporation Compositions and methods relating to target-specific photodynamic therapy
CN101485629B (zh) * 2008-01-16 2013-01-23 沈阳药科大学 一种给药系统及其制备方法
JP2011517683A (ja) * 2008-04-10 2011-06-16 アブラクシス バイオサイエンス， エルエルシー 疎水性タキサン誘導体の組成物およびその使用
US8815931B2 (en) * 2009-04-28 2014-08-26 Biolitec Pharma Marketing Ltd Oral formulations for tetrapyrrole derivatives
WO2010127269A1 (en) * 2009-04-30 2010-11-04 Thermo Niton Analyzers Llc Localization of an element of interest by xrf analysis of different inspection volumes
US20110275686A1 (en) * 2009-12-11 2011-11-10 Biolitec, Inc. Nanoparticle carrier systems based on poly(dl-lactic-co-glycolic acid) (plga) for photodynamic therapy (pdt)

Also Published As

Publication number Publication date
CN102740875A (zh) 2012-10-17
WO2011071968A2 (en) 2011-06-16
US9211283B2 (en) 2015-12-15
JP2013513609A (ja) 2013-04-22
EP2509620A4 (en) 2015-10-21
WO2011071968A3 (en) 2011-11-17
JP5972171B2 (ja) 2016-08-17
EP2509620A2 (en) 2012-10-17
CA2784001C (en) 2018-04-10
US20110142948A1 (en) 2011-06-16
CA2784001A1 (en) 2011-06-16

Similar Documents

Publication Publication Date Title
US9211283B2 (en) Nanoparticle carrier systems based on human serum albumin for photodynamic therapy
EP2509633B1 (en) Nanoparticle carrier system based on poly(dl-lactic-co-glycolic acid) (plga) for photodynamic therapy
Konan et al. Enhanced photodynamic activity of meso-tetra (4-hydroxyphenyl) porphyrin by incorporation into sub-200 nm nanoparticles
KR102081666B1 (ko) 암 치료용 약학 조성물
US8815931B2 (en) Oral formulations for tetrapyrrole derivatives
CN112076319B (zh) 青蒿素及其衍生物在制备热动力治疗敏化剂中的应用
EP1503796B1 (en) Compositions and methods for delivery of photosensitive drugs
KR20080095182A (ko) 고분자 유도체-광감작제 복합체를 이용한 새로운 광역학치료제
KR20110101338A (ko) 광역학 진단 또는 치료를 위한 생체 적합성 고분자와 광감작제의 결합체 및 이의 제조방법
Gualdesi et al. Synthesis and physicochemical properties of polyacrylamide nanoparticles as photosensitizer carriers
KR102363327B1 (ko) 5-아미노레불린산 수화염화물을 포함하는 광역학 치료용 조성물
CN101524326A (zh) 一种二氢卟吩e6壳聚糖-硬脂酸嫁接物胶束
Dong et al. Investigation of the intracellular oxidative stress amplification, safety and anti-tumor effect of a kind of novel redox-responsive micelle
da Silva et al. In vitro photodynamic activity of chloro (5, 10, 15, 20-tetraphenylporphyrinato) indium (III) loaded-poly (lactide-co-glycolide) nanoparticles in LNCaP prostate tumour cells
Huang et al. Nanogenerators with l-arginine loading: new choices as cascade and synergistic nitric oxide/photodynamic antitumor agents
Sadykova et al. Polymer photosensitizing systems containing porphyrins, dinitrosyl iron complexes, and sodium alginate in the generation of singlet oxygen
CN113827553B (zh) 用于肿瘤光动力学治疗的瘤内注射给药的酞菁锌在位凝胶及其制备方法
Shabbirahmed et al. Recent advancements in nanomaterials for photodynamic therapy of cancers
US11040101B2 (en) Nanoparticles for cancer therapy and diagnosis
EP3041510B1 (en) Polymer micelle containing a photosensitizer
US20220402763A1 (en) Graphene oxide (go)-based composite nanoparticle drug delivery system and preparation method thereof
BRPI0803473A2 (pt) nanopartìcula transportadora de fármacos, processo de preparo e composição farmacêutica compreendendo a mesma e método para entrega de fármacos
Amirinejad et al. Structural Design and Modification of Porphyrin-Based Nanovesicles for Enhanced Biomedical Functionality
Lai et al. Shell Cross-Linked Nanoparticle Based on Poly (ε-caprolactone)-Poly (ethylene glycol) for Photosensitizer Delivery
CZ2016119A3 (cs) Fotoaktivovatelná nanočástice pro fotodynamické aplikace, způsob její přípravy, farmaceutická kompozice ji obsahující a jejich použití

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2544 DE 08-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.